免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

Sepsis Biomarker Monitoring in Burn Patients

NCT: NCT07866521 · NOT_YET_RECRUITING

NCT識別子NCT07866521
ステータスNOT_YET_RECRUITING
開始日2026-11-01
完了2028-08-31
SponsorTexas Tech University Health Sciences Center (OTHER)
First posted
Last updated

概要

The goal of this clinical trial is to learn if using pancreatic stone protein (PSP) test results helps doctors find and treat sepsis earlier in adults with serious burn injuries. The study will also look at whether using PSP is safe and practical in the burn intensive care unit. The main questions it aims to answer are: * Does seeing PSP test results help doctors start the right antibiotics sooner? * Does using PSP reduce unnecessary antibiotic use? * Does using PSP improve recovery and other health outcomes? Researchers will compare two groups of patients. One group will receive standard care, and their PSP test results will be hidden from their care team. The other group will receive standard care, but their care team will be able to see the PSP test results and use them to help make treatment decisions. Participants will: * Be randomly assigned to one of the two study groups. * Have a small blood sample taken within 24 hours after being admitted to the burn ICU and then once each weekday while they are in the ICU. * Receive the usual care for burn injuries and sepsis throughout the study.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑